PADI4

Across TCGA pan-cancer cohorts, PADI4 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated PADI4 data layer compared with 8 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PADI4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PADI4 expression acts as an unfavorable survival marker, although some lineages such as CHOL and SCLC show a favorable association.

LUSC, THCA, and CESC are the cancer types where PADI4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Quartile	All	0.578	0.723	.002	37	view →
THCA	OS	Median	II,III,IV	0.758	1.000	<.001	32	view →
CESC	DFS	Quartile	III,IV	0.147	0.668	.008	24	view →
CHOL	DFS	Median	III,IV	0.647	0.127	.006	24	view →
SCLC	DFS	Median	All	0.404	0.116	.002	18	view →
ESCA	OS	Median	All	0.440	1.000	.008	17	view →
ACC	OS	Median	II,III,IV	0.749	0.954	.007	16	view →
OV	OS	Tertile	IV	0.573	0.903	.019	14	view →
LIHC	OS	Median	III,IV	0.716	0.332	.002	14	view →
THYM	OS	Median	All	1.000	0.922	.012	13	view →
PCPG	DFS	Median	All	0.638	0.905	.004	12	view →
LGG	OS	Tertile	All	0.968	0.877	.004	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

PADI4–LUSC (OS)

Open the LUSC breakdown →